Heamclas-FCM Injection contains Ferric Carboxymaltose (50 mg/ml), an intravenous iron preparation indicated for the treatment of iron deficiency anemia when oral iron therapy is ineffective or cannot be used. Ferric Carboxymaltose is a stable complex that allows controlled release of bioavailable iron, facilitating rapid replenishment of iron stores and hemoglobin synthesis. This formulation is particularly beneficial in patients with chronic kidney disease, postpartum anemia, or those undergoing chemotherapy, where timely correction of iron deficiency is critical. The injection is administered intravenously, enabling efficient iron delivery directly into the bloodstream, bypassing gastrointestinal absorption limitations. Dosage and infusion rates should be tailored according to individual patient iron requirements, hemoglobin levels, and clinical response, with monitoring for potential hypersensitivity reactions. Common adverse effects may include transient nausea, headache, dizziness, or injection site reactions. Heamclas-FCM Injection should be used cautiously in patients with known hypersensitivity to iron products or those with iron overload disorders. Proper patient evaluation, including serum ferritin and transferrin saturation assessments, is recommended prior to administration to ensure appropriate use. This preparation offers a convenient and effective option for rapid iron repletion in diverse clinical settings.